Cargando…

The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England

The emergence of the B.1.1.529 (Omicron) variant caused international concern due to its rapid spread in Southern Africa. It was unknown whether this variant would replace or co-exist with (either transiently or long-term) the then-dominant Delta variant on its introduction to England. We developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Paton, Robert S., Overton, Christopher E., Ward, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097877/
https://www.ncbi.nlm.nih.gov/pubmed/35503007
http://dx.doi.org/10.1126/scitranslmed.abo5395
_version_ 1784706261817753600
author Paton, Robert S.
Overton, Christopher E.
Ward, Thomas
author_facet Paton, Robert S.
Overton, Christopher E.
Ward, Thomas
author_sort Paton, Robert S.
collection PubMed
description The emergence of the B.1.1.529 (Omicron) variant caused international concern due to its rapid spread in Southern Africa. It was unknown whether this variant would replace or co-exist with (either transiently or long-term) the then-dominant Delta variant on its introduction to England. We developed a set of hierarchical logistic growth models to describe changes in the frequency of S gene target failure (SGTF) PCR tests, which was a proxy for Omicron. The doubling time of SGTF cases peaked at 1.56 days (95% CI: 1.49, 1.63) on the 5(th) of December, while triple positive cases were halving every 5.82 days (95% CI: 5.11, 6.67) going into Christmas 2021. We were unable to characterize the replacement of Delta by Omicron with a single rate. The replacement rate decreased by 53.56% (95% CrI: 45.38, 61.01) between the 14(th) and 15(th) of December, meaning the competitive advantage of Omicron approximately halved. Preceding the changepoint, Omicron was replacing Delta 16.24% (95% CrI: 9.72, 23.41) faster in those with two or more vaccine doses, indicative of vaccine escape being a substantial component of the competitive advantage. Despite the slowdown, Delta had almost entirely been replaced in England within a month of the first sequenced domestic case. The synchrony of changepoints across regions at various stages of Omicron epidemics suggests that the growth rate advantage was not attenuated due to biological mechanisms related to strain competition. The step-change in replacement could have resulted from behavioral changes, potentially elicited by public health messaging or policies, that differentially affected Omicron.
format Online
Article
Text
id pubmed-9097877
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-90978772022-05-17 The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England Paton, Robert S. Overton, Christopher E. Ward, Thomas Sci Transl Med Research Articles The emergence of the B.1.1.529 (Omicron) variant caused international concern due to its rapid spread in Southern Africa. It was unknown whether this variant would replace or co-exist with (either transiently or long-term) the then-dominant Delta variant on its introduction to England. We developed a set of hierarchical logistic growth models to describe changes in the frequency of S gene target failure (SGTF) PCR tests, which was a proxy for Omicron. The doubling time of SGTF cases peaked at 1.56 days (95% CI: 1.49, 1.63) on the 5(th) of December, while triple positive cases were halving every 5.82 days (95% CI: 5.11, 6.67) going into Christmas 2021. We were unable to characterize the replacement of Delta by Omicron with a single rate. The replacement rate decreased by 53.56% (95% CrI: 45.38, 61.01) between the 14(th) and 15(th) of December, meaning the competitive advantage of Omicron approximately halved. Preceding the changepoint, Omicron was replacing Delta 16.24% (95% CrI: 9.72, 23.41) faster in those with two or more vaccine doses, indicative of vaccine escape being a substantial component of the competitive advantage. Despite the slowdown, Delta had almost entirely been replaced in England within a month of the first sequenced domestic case. The synchrony of changepoints across regions at various stages of Omicron epidemics suggests that the growth rate advantage was not attenuated due to biological mechanisms related to strain competition. The step-change in replacement could have resulted from behavioral changes, potentially elicited by public health messaging or policies, that differentially affected Omicron. American Association for the Advancement of Science 2022-05-03 /pmc/articles/PMC9097877/ /pubmed/35503007 http://dx.doi.org/10.1126/scitranslmed.abo5395 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Paton, Robert S.
Overton, Christopher E.
Ward, Thomas
The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
title The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
title_full The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
title_fullStr The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
title_full_unstemmed The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
title_short The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
title_sort rapid replacement of the delta variant by omicron (b.1.1.529) in england
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097877/
https://www.ncbi.nlm.nih.gov/pubmed/35503007
http://dx.doi.org/10.1126/scitranslmed.abo5395
work_keys_str_mv AT patonroberts therapidreplacementofthedeltavariantbyomicronb11529inengland
AT overtonchristophere therapidreplacementofthedeltavariantbyomicronb11529inengland
AT wardthomas therapidreplacementofthedeltavariantbyomicronb11529inengland
AT patonroberts rapidreplacementofthedeltavariantbyomicronb11529inengland
AT overtonchristophere rapidreplacementofthedeltavariantbyomicronb11529inengland
AT wardthomas rapidreplacementofthedeltavariantbyomicronb11529inengland